Christensen, Signe M.,Mikkelsen, Nikolaj Dam,Frieden, Miriam,Hansen, Henrik Frydenlund,Koch, Troels,Pedersen, Daniel-Sejer,Rosenbohm, Christoph,Thrue, Charlotte Albaek,Westergaard, Majken
申请号：
AU2011201821
公开号：
AU2011201821B2
申请日:
2011.04.20
申请国别(地区):
AU
年份:
2013
代理人:
摘要：
#$%^&*AU2011201821B220131010.pdf#####Abstract A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta--D-thio/amino-LNA or alpha-L-oxy/thio/aminoLNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
